T1D RESEARCH BREAKTHROUGHS
THE TOP RESEARCH PROGRESS IN 2018 ~ SUPPORTED BY JDRF
CGMs IMPROVE HEALTH IN PREGNANCY
An international trial CONCEPTT found that pregnant women living with T1D who used a CGM during their pregnancy had better blood glucose control and healthier babies compared to women who did not use a CGM.
INSULIN PUMP SYSTEM REDUCES HYPOS
In an Australian trial, researchers found a pump that suspends insulin delivery when blood glucose levels fall can halve the amount of time spent in hypoglycaemia in young people with T1D.
BETA CELLS STABILISE AFTER 7YRS
Contrary to older beliefs, new research has found insulin production rapidly declines after diagnosis then stabilises after seven years. This opens new doors to develop methods to preserve and regenerate beta cells in the pancreas years after diagnosis
DRUGS REDUCE EARLY SIGNS OF KIDNEY DISEASE IN YOUNG ADULTS WITH T1D
A global adolescentT1D study has found drugs used to treat blood pressure and cholesterol in adults can reduce the risk of kidney disease in young people with T1D.
IMMUNOTHERAPY HAS THE POTENTIAL TO DELAY THE PROGRESS OF T1D
UK researchers tested a new immune therapy in humans for the first time and found that it was safe and has the potential to delay progression of T1D.
BLOOD PRESSURE DRUG BOOSTS INSULIN PRODUCTION
UK researchers found a common blood pressure drug called verapamil protected working beta cells and boosted insulin production in adults with recently diagnosed T1D.
COMBINATION IMMUNOTHERAPY PRESERVES BETA CELL FUNCTION
Global prevention group TrialNet found low dose immune therapy preserves beta cell function, improves insulin production and reduces HbA1c in recently diagnosed individuals with T1D.
AUSTRALIAN RESEARCHERS IDENTIFY WHICH BABIES COULD DEVELOP T1D
Researchers identified a seven-gene ‘signature’ in babies under 12 months old, which when combined with a genetic risk score, identified those with a high-risk of developing T1D.